Isotope choice and the effect of edema on prostate brachytherapy dosimetry

被引:18
作者
Butler, WM
Merrick, GS
Dorsey, AT
Lief, JH
机构
[1] Wheeling Hosp, Schiffler Oncol Ctr, Wheeling, WV 26003 USA
[2] George Washington Univ, Med Ctr, Div Radiat Oncol & Biophys, Washington, DC 20037 USA
[3] Wheeling Jesuit Univ, Wheeling, WV 26003 USA
关键词
prostate brachytherapy; edema; I-125; Pd-103; dose-volume histograms;
D O I
10.1118/1.598972
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In prostate brachytherapy, post implant dosimetry quality parameters may be strongly affected by edema brought on by the trauma of the implant procedure since the amount of edema and the time course of its resolution are highly variable from patient to patient. Edema was simulated from preplans on three prostates which had ultrasound prostate volumes of 18.7, 40.7 and 60.2 cm(3) expanded to planning volumes of 32.9, 60.0 and 87.8 cm(3), respectively. The preplans were designed so that identical seed distributions for a given prostate gave virtually identical target dose coverage of 99.7 +/- 0.3% of the planning volume when using either I-125 Or Pd-103. Simulated CT edema volume expansions of 0%, 10%, 20% and 30% were imposed anisotropically in accordance with clinical observations so that the expansion in the superior-inferior direction was twice that of the transverse dimensions. Dose-volume histograms (DVHs) were analyzed for each prostate as a function of isotope and degree of edema. The Pd-103 implants were more greatly affected by fixed amounts of edema than I-125 implants, and the slopes of the DVH curves indicate less homogeneity from Pd-103 implants. The DVHs were then weighted according to the portion of the isotope decay curve occupied by each edema step for half-lives of edema resolution of 5, 10 and 20 days which are within the range of clinically observed resolution times. The weighted DVHs were summed to give a net DVH. corresponding to the overall dynamic effect of edema. A greater fraction of the defined prostate volume received doses in the range of likely therapeutic significance, from 75% to 125% of the prescribed minimal peripheral dose (mPD), from I-125 implants than from Pd-103 implants. These differences in dosimetric quality arise from two differences in the physical properties of the isotopes: more rapid attenuation of Pd-103 photons with distance creates cool spots in an edematous prostate, and the shorter half-life of Pd-103 causes a greater fraction of the isotope decay to consist of the prostate in an edematous state. An increase in Pd-103 seed strength by about 10% beyond that required to achieve equal coverage with an identical seed distribution using I-125 should minimize the differences brought on by edema. (C) 2000 American Association of Physicists in Medicine. [S0094-2405(00)01505-4].
引用
收藏
页码:1067 / 1075
页数:9
相关论文
共 31 条
[11]   Potential role of various dosimetric quality indicators in prostate brachytherapy [J].
Merrick, GS ;
Butler, WM ;
Dorsey, AT ;
Lief, JH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (03) :717-724
[12]  
MERRICK GS, 1998, J BRACHYTHERAPY INT, V14, P113
[13]   Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging [J].
Moerland, MA ;
Wijrdeman, HK ;
Beersma, R ;
Bakker, CJG ;
Battermann, JJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (04) :927-933
[14]   DOSIMETRY OF INTERSTITIAL BRACHYTHERAPY SOURCES - RECOMMENDATIONS OF THE AAPM RADIATION-THERAPY COMMITTEE TASK GROUP NO 43 [J].
NATH, R ;
ANDERSON, LL ;
LUXTON, G ;
WEAVER, KA ;
WILLIAMSON, JF ;
MEIGOONI, AS .
MEDICAL PHYSICS, 1995, 22 (02) :209-234
[15]   Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy [J].
Prestidge, BR ;
Bice, WS ;
Kiefer, EJ ;
Prete, JJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (05) :1111-1115
[16]  
PRESTIDGE BR, 1997, INT J RADIAT ONCOL, V39, P238
[17]  
Ragde H, 1997, SEMIN SURG ONCOL, V13, P438, DOI 10.1002/(SICI)1098-2388(199711/12)13:6<438::AID-SSU8>3.0.CO
[18]  
2-B
[19]  
Ragde H, 1997, CANCER, V80, P442, DOI 10.1002/(SICI)1097-0142(19970801)80:3<442::AID-CNCR12>3.0.CO
[20]  
2-X